Treatment with IL-15 combined with PD-1 blockade promotes the secretion of IFN-γ, perforin, and granzyme B, thereby enhancing the activation status and antitumor efficacy of NK cells in AML patients. This evidence concerns the gene PDCD1 and acute myeloid leukemia.